RNA Epitranscriptomics Gotham Therapeutics targets RNA-modifying proteins to create a novel drug class, aiming to modulate the epitranscriptome. The focus spans cancers, autoimmune diseases, and neurodegenerative conditions, signaling a potentially multi-indication pipeline attractive to pharma partners.

Outsourced Discovery With a very small internal team, Gotham relies on external collaborations for discovery and development. The company has previously partnered with Mercachem and ZoBio to generate compound libraries and accelerate hit generation, indicating a viable path for CRO led discovery partnerships.

Funding Momentum Funding and modest revenue signals suggest readiness for partnerships that include upfronts, milestones, and royalties to monetize the pipeline while sharing development risk with larger partners.

Partnership Track Past collaborations and notable investors demonstrate credibility and a proven openness to co development. This history provides a solid foothold for business development teams targeting joint discovery, optimization, and translational collaborations.

Acquisition Signals Broader acquisition activity in the RNA targeting space indicates potential strategic interest from buyers or licensing partners for an asset portfolio, offering avenues for licensing or joint development deals.